Literature DB >> 15588720

Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

Giuseppina Raspaglio1, Cristiano Ferlini, Simona Mozzetti, Silvia Prislei, Daniela Gallo, Nandita Das, Giovanni Scambia.   

Abstract

During a cellular screening of thiocolchicine analogs, thiocolchicine dimers resulted particularly active in cisplatin-resistant A2780-CIS cells. In order to discover by which mechanism(s) thiocolchicine dimers overcame cisplatin resistance, p53, p21waf1 and MLH1 were assessed by Western blot. Results pointed out that, when combined with cisplatin, dimers increased the amount of all the three proteins with respect to the levels obtained by single drug exposure, thereby suggesting an interference in the process of repair of the cisplatin-induced DNA lesions. Moreover, in isolated nuclei drugs were able to produce DNA breaks, as demonstrated by Comet assay, thereby proving that the compounds were able to target cell nucleus independently from microtubules. Since Topo-I (topoisomerase I) is directly involved in the DNA repair and such activity is overexpressed in cisplatin-resistant cells, Topo-I was investigated as a potential target. Using DNA relaxation assay, thiocolchicine dimers inhibited Topo-I, a property not shared by thiocolchicine. At variance with camptothecin, dimers did not produce cleavable complexes, thereby indicating that Topo-I inhibition occurs upstream of the religation step. To assess the mechanism of inhibition, an electrophoretic mobility shift assay between DNA and Topo-I was performed and revealed that thiocolchicine dimers specifically interfere with binding of Topo-I to DNA. The interference is specific since the same compounds did not modulate DNase activity and did not act as intercalating agents in the DNA unwinding assay. Finally, behaviour of dimers as spindle poisons was investigated and no relevant changes with respect to thiocolchicine in terms of interaction with microtubules were found.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15588720     DOI: 10.1016/j.bcp.2004.09.004

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.

Authors:  Ning Wu; Xi-Wei Wu; Keli Agama; Yves Pommier; Jun Du; Ding Li; Lian-Quan Gu; Zhi-Shu Huang; Lin-Kun An
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

2.  DNA-Binding and Topoisomerase-I-Suppressing Activities of Novel Vanadium Compound Van-7.

Authors:  Xiao-Mei Mo; Zhan-Fang Chen; Xin Qi; Yan-Tuan Li; Jing Li
Journal:  Bioinorg Chem Appl       Date:  2012-09-30       Impact factor: 7.778

3.  Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents.

Authors:  Urszula Majcher; Greta Klejborowska; Magdalena Kaik; Ewa Maj; Joanna Wietrzyk; Mahshad Moshari; Jordane Preto; Jack A Tuszynski; Adam Huczyński
Journal:  Cells       Date:  2018-11-19       Impact factor: 6.600

Review 4.  Double the Chemistry, Double the Fun: Structural Diversity and Biological Activity of Marine-Derived Diketopiperazine Dimers.

Authors:  Nelson G M Gomes; Renato B Pereira; Paula B Andrade; Patrícia Valentão
Journal:  Mar Drugs       Date:  2019-09-27       Impact factor: 5.118

Review 5.  Towards principled design of cancer nanomedicine to accelerate clinical translation.

Authors:  Mohammad Souri; M Soltani; Farshad Moradi Kashkooli; Mohammad Kiani Shahvandi; Mohsen Chiani; Fatemeh Sadat Shariati; Mohammad Reza Mehrabi; Lance L Munn
Journal:  Mater Today Bio       Date:  2022-02-01

6.  3EZ,20Ac-ingenol, a catalytic inhibitor of topoisomerases, downregulates p-Akt and induces DSBs and apoptosis of DT40 cells.

Authors:  Yasuaki Fukuda; Masahiro Kanbe; Manami Watanabe; Katsuaki Dan; Keiichi Matsuzaki; Susumu Kitanaka; Shohei Miyata
Journal:  Arch Pharm Res       Date:  2013-04-18       Impact factor: 4.946

7.  Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives.

Authors:  Urszula Majcher; Greta Klejborowska; Mahshad Moshari; Ewa Maj; Joanna Wietrzyk; Franz Bartl; Jack A Tuszynski; Adam Huczyński
Journal:  Cells       Date:  2018-11-01       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.